News | March 10, 2026
AbbVie reports promising early results for novel obesity therapy ABBV-295
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The company announced positive topline data from the Phase II ZUPREME-1 trial
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
